Key Takeaways
Hansoh Pharmaceutical Group (3692.HK) will transfer its Greater China license for an approved osteoarthritis treatment to Jiangsu Hengrui Pharmaceuticals (600276.SS) for RMB 131 million, exiting the project as part of a strategic portfolio review.
The board said the deal aligns with Hansoh’s long-term strategic focus while positioning the product with a partner better equipped for its commercial rollout. Hengrui is a leading pharmaceutical company in China with an extensive presence in the orthopedics market.
The product, KiOmedine vs One, is an intra-articular knee injection developed by Belgium-based KiOmed Pharma SA. While it was approved by China’s National Medical Products Administration (NMPA) as a medical device in August 2025, Hansoh had not yet commercialized it. The RMB 131 million transfer price was calculated to allow Hansoh to recover its licensing payments and development expenses.
The transaction allows Hansoh to monetize a non-core asset and recover sunk R&D costs, sharpening its focus on other therapeutic areas. For Hengrui, the deal provides a ready-to-launch product that fits directly into its established orthopedics franchise, strengthening its portfolio in the osteoarthritis market. Hansoh originally secured the exclusive license for Mainland China, Hong Kong, Macau, and Taiwan in September 2022.
This deal sharpens Hansoh's focus on its core pipeline and demonstrates a disciplined approach to capital allocation. For Hengrui, the acquisition presents an immediate opportunity to leverage its orthopedic sales channels, with investors watching for a commercial launch timeline.
This article is for informational purposes only and does not constitute investment advice.
